Michelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, Thuy T Koll, Christina K Cramer, Glenn J Lesser, Debra L Barton, Karen M Mustian, Lynne I Wagner, Patricia A Ganz, Peter D Cole, Alexis Bakos, James C Root, Kristina Hardy, Allison Magnuson, Robert J Ferguson, Brenna C McDonald, Andrew J Saykin, Brian D Gonzalez, Jeffrey S Wefel, David A Morilak, Saurabh Dahiya, Cobi J Heijnen, Yvette P Conley, Alicia K Morgans, Donald Mabbott, Michelle Monje, Stephen R Rapp, Vinai Gondi, Catherine Bender, Leanne Embry, Worta McCaskill Stevens, Judith O Hopkins, Diane St Germain, Susan G Dorsey
Cancer-related cognitive impairment (CRCI) is a broad term encompassing subtle cognitive problems to more severe impairment. CRCI severity is influenced by host, disease, and treatment factors and affects patients prior to, during, and following cancer treatment. The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee (SxQoL SC) convened a Clinical Trial Planning Meeting (CTPM) to review the state of the science on CRCI and to develop both Phase II/III intervention trials aimed at improving cognitive function in cancer survivors with non-central nervous system (CNS) disease and longitudinal studies to understand the trajectory of cognitive impairment and contributing factors...
September 9, 2024: Journal of the National Cancer Institute